Peplin, Inc. company is developing drugs aimed at treating potentially cancerous skin conditions. Its lead drug candidate, a topical gel, is intended to serve as a less-costly alternative to surgical treatments for a common pre-cancerous skin condition known as actinic keratosis (AK). Derived from a plant known as petty spurge or radium weed, the product will be used to treat AK (characterized by rough patches of skin resulting from excessive exposure to sunlight) before it develops into skin cancer. Peplin was acquired by pharmaceutical giant LEO Pharma in late 2009 for $285 million.

Forest Laboratories, Inc. was founded in 1956 and is based in New York, New York. Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro to treat depression; Namenda to treat Alzheimer's disease; Bystolic, beta-blocker to treat hypertension; and Savella for the treatment of fibromyalgia. The company also provides Sudocrem, a topical preparation to treat diaper rash; Colomycin, an antibiotic to treat cystic fibrosis; Infacol, which is used to treat infant colic; and Exorex, which is to treat eczema and psoriasis. In addition, its products include Dutogliptin, a small molecule dipeptidyl-peptidase-4 inhibitor, which is in Phase III studies to treat Type II diabetes mellitus; F2695 that completed Phase II study and is a selective norepinephrine and serotonin reuptake inhibitor for the treatment of depression and other central nervous system disorders; and ceftaroline acetate, a injectable cephalosporin antibiotic that exhibits bactericidal activity against the strains of gram-positive bacteria.Forest Laboratories'sproducts comprise NXL104, an intravenous beta-lactamase inhibitor; Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, an inhaling therapy, which is in Phase III studies for chronic obstructive pulmonary disease; and Cariprazine, an atypical antipsychotic in Phase II(b) studies for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. Additionally, its products include Oglemilast, a phosphodiesterase-IV inhibitor in Phase II study to treat COPD and asthma; and Benicar, an angiotensin receptor blocker to treat hypertension. The company has collaboration and license agreements Phenomix Corporation, Pierre Fabre Medicament, Novexel, S.A., Laboratorios Almirall, S.A., Gedeon Richter Ltd., Glenmark Pharmaceuticals Ltd., and AstraZeneca plc.

Afexa Life Sciences (formerly CV Technologies) bets that mother nature is always right, but it offers a guarantee just in case. The company uses its ChemBioPrint technology to identify and measure the contents and biological activity of natural health products to ensure batches of herbs and natural compounds are safe and consistent. The company originated as a spin-off from the Faculty of Medicine at the University of Alberta in 1992, and now focuses on the development and manufacturing of natural health products for disease prevention and health maintenance for everyday consumers, especially athletes. COLD-fX is Afexa's lead product and works to strengthen the immune system to prevent colds and the flu.

MDRNA, Inc. company was founded in 1983 and is headquartered in Bothell, Washington. MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Accentia Biopharmaceuticals, Inc. (Accentia) is a biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease and oncology. The Company operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products with an emphasis on the respiratory and oncology therapeutic areas. The products developed in this segment are SinuNase, BiovaxID and Revimmune. This segment also includes the Company’s consulting business, which provides a range of services relating to biopharmaceutical product development, and its biologics products business. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by its third-party development partners. In this segment, Accentia sells the Respi~TANN, SinuTest and Zinotic.

PLIVA wants you to remember its scientific research and business acumen, and less the names of its products. PLIVA company develops and produces generic pharmaceuticals, particularly in the anti-inflammatory and anti-infective areas. PLIVA also produces the active pharmaceutical ingredients used by other drug makers. Its products include both prescription and over-the-counter drugs, pills, creams, and injectables. PLIVA was founded in 1921 and operates in more than 30 countries. The company is a subsidiary of global generics firm Teva Pharmaceutical.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

RemoteMDx, Inc., together with its subsidiaries, markets and deploys offender management programs, combining patented global positioning system tracking technologies, intervention-based monitoring capabilities, and case management services in the United States. It markets, monitors, and sells the TrackerPAL device, which is used to monitor convicted offenders that are on probation or parole in the criminal justice system. The TrackerPAL device utilizes global positioning system and cellular technologies in conjunction with a monitoring center. The company also sells home security and personal emergency response systems. RemoteMDx, Inc. has strategic relationships with Puracom, Inc.; Inovar, Inc.; and euromicron AG. The company is headquartered in Sandy, Utah.

Cerus Corporation company was founded in 1991 and is based in Concord, California. Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company’s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.